KR102122617B1 - Tor 키나제 억제자를 사용하는 암의 치료 - Google Patents

Tor 키나제 억제자를 사용하는 암의 치료 Download PDF

Info

Publication number
KR102122617B1
KR102122617B1 KR1020147028707A KR20147028707A KR102122617B1 KR 102122617 B1 KR102122617 B1 KR 102122617B1 KR 1020147028707 A KR1020147028707 A KR 1020147028707A KR 20147028707 A KR20147028707 A KR 20147028707A KR 102122617 B1 KR102122617 B1 KR 102122617B1
Authority
KR
South Korea
Prior art keywords
substituted
pyrazin
unsubstituted
methyl
tor kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147028707A
Other languages
English (en)
Korean (ko)
Other versions
KR20140138927A (ko
Inventor
슈이찬 주
크리스튼 메이 헤게
헤더 레이몬
릴리 로레인 웡
Original Assignee
시그날 파마소티칼 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시그날 파마소티칼 엘엘씨 filed Critical 시그날 파마소티칼 엘엘씨
Publication of KR20140138927A publication Critical patent/KR20140138927A/ko
Application granted granted Critical
Publication of KR102122617B1 publication Critical patent/KR102122617B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147028707A 2012-03-15 2013-03-14 Tor 키나제 억제자를 사용하는 암의 치료 Active KR102122617B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261611361P 2012-03-15 2012-03-15
US61/611,361 2012-03-15
US201261715323P 2012-10-18 2012-10-18
US61/715,323 2012-10-18
PCT/US2013/031206 WO2013138557A1 (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207016306A Division KR20200070416A (ko) 2012-03-15 2013-03-14 Tor 키나제 억제자를 사용하는 암의 치료

Publications (2)

Publication Number Publication Date
KR20140138927A KR20140138927A (ko) 2014-12-04
KR102122617B1 true KR102122617B1 (ko) 2020-06-12

Family

ID=48014336

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020147028707A Active KR102122617B1 (ko) 2012-03-15 2013-03-14 Tor 키나제 억제자를 사용하는 암의 치료
KR1020207016306A Ceased KR20200070416A (ko) 2012-03-15 2013-03-14 Tor 키나제 억제자를 사용하는 암의 치료
KR1020217017407A Ceased KR20210071101A (ko) 2012-03-15 2013-03-14 Tor 키나제 억제자를 사용하는 암의 치료

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020207016306A Ceased KR20200070416A (ko) 2012-03-15 2013-03-14 Tor 키나제 억제자를 사용하는 암의 치료
KR1020217017407A Ceased KR20210071101A (ko) 2012-03-15 2013-03-14 Tor 키나제 억제자를 사용하는 암의 치료

Country Status (21)

Country Link
US (1) US20130245026A1 (cg-RX-API-DMAC7.html)
EP (1) EP2825170B1 (cg-RX-API-DMAC7.html)
JP (3) JP2015510891A (cg-RX-API-DMAC7.html)
KR (3) KR102122617B1 (cg-RX-API-DMAC7.html)
CN (2) CN104519885A (cg-RX-API-DMAC7.html)
AU (1) AU2013203153B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014022703A2 (cg-RX-API-DMAC7.html)
CA (1) CA2866872A1 (cg-RX-API-DMAC7.html)
EA (1) EA028414B1 (cg-RX-API-DMAC7.html)
ES (1) ES2677874T3 (cg-RX-API-DMAC7.html)
IL (1) IL234602B (cg-RX-API-DMAC7.html)
MX (1) MX360878B (cg-RX-API-DMAC7.html)
MY (1) MY174022A (cg-RX-API-DMAC7.html)
NI (1) NI201400111A (cg-RX-API-DMAC7.html)
NZ (1) NZ628416A (cg-RX-API-DMAC7.html)
PH (1) PH12014502029B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201405707XA (cg-RX-API-DMAC7.html)
TW (1) TWI583385B (cg-RX-API-DMAC7.html)
UA (1) UA114315C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013138557A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201406706B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA028414B1 (ru) * 2012-03-15 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Лечение рака ингибиторами tor киназы
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
SG11201505446WA (en) 2013-01-16 2015-08-28 Signal Pharm Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
HK1221168A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
US20140314673A1 (en) * 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
JP6382946B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
CA2908742C (en) * 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
MY189663A (en) 2013-04-17 2022-02-23 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
WO2014172425A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
EP3549940A1 (en) 2013-04-17 2019-10-09 Signal Pharmaceuticals, LLC Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
CN107474051B (zh) 2013-05-29 2020-10-30 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2016010886A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008051494A1 (en) * 2006-10-19 2008-05-02 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
WO2008051493A2 (en) * 2006-10-19 2008-05-02 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
WO2010022243A1 (en) * 2008-08-20 2010-02-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemoprevention of head and neck squamous cell carcinomas
WO2010062571A1 (en) * 2008-10-27 2010-06-03 Signal Pharmaceuticals, Llc Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/p13k/akt pathway

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ599549A (en) 2009-10-26 2013-11-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
US20120028972A1 (en) * 2010-07-30 2012-02-02 Lilly Wong Biomarker assays for detecting or measuring inhibition of tor kinase activity
EA028414B1 (ru) * 2012-03-15 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Лечение рака ингибиторами tor киназы

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008051494A1 (en) * 2006-10-19 2008-05-02 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
WO2008051493A2 (en) * 2006-10-19 2008-05-02 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
WO2010022243A1 (en) * 2008-08-20 2010-02-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemoprevention of head and neck squamous cell carcinomas
WO2010062571A1 (en) * 2008-10-27 2010-06-03 Signal Pharmaceuticals, Llc Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/p13k/akt pathway

Also Published As

Publication number Publication date
WO2013138557A1 (en) 2013-09-19
TW201343168A (zh) 2013-11-01
NI201400111A (es) 2015-01-15
AU2013203153B2 (en) 2015-09-03
BR112014022703A2 (pt) 2021-05-04
NZ628416A (en) 2016-04-29
JP2019108368A (ja) 2019-07-04
PH12014502029A1 (en) 2014-11-24
ZA201406706B (en) 2016-05-25
TWI583385B (zh) 2017-05-21
JP2021102637A (ja) 2021-07-15
KR20140138927A (ko) 2014-12-04
EA028414B1 (ru) 2017-11-30
EA201491699A1 (ru) 2015-02-27
CA2866872A1 (en) 2013-09-19
IL234602B (en) 2020-05-31
SG11201405707XA (en) 2014-10-30
HK1201750A1 (en) 2015-09-11
CN104519885A (zh) 2015-04-15
MX2014011077A (es) 2014-10-14
CN108992446A (zh) 2018-12-14
KR20200070416A (ko) 2020-06-17
JP2015510891A (ja) 2015-04-13
MY174022A (en) 2020-03-04
ES2677874T3 (es) 2018-08-07
EP2825170B1 (en) 2018-05-09
KR20210071101A (ko) 2021-06-15
EP2825170A1 (en) 2015-01-21
IL234602A0 (en) 2014-11-30
UA114315C2 (uk) 2017-05-25
AU2013203153A1 (en) 2013-10-03
PH12014502029B1 (en) 2014-11-24
US20130245026A1 (en) 2013-09-19
MX360878B (es) 2018-11-21

Similar Documents

Publication Publication Date Title
US20230338370A1 (en) Treatment of Cancer with TOR Kinase Inhibitors
JP6470822B2 (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
EP2825170B1 (en) Treatment of cancer with tor kinase inhibitors
EP2825168B1 (en) Treatment of cancer with tor kinase inhibitors
AU2015213400B2 (en) Treatment of cancer with TOR kinase inhibitors
HK1201750B (en) Treatment of cancer with tor kinase inhibitors
HK1202247B (en) Treatment of cancer with tor kinase inhibitors
HK1201755B (en) Treatment of cancer with tor kinase inhibitors
HK1201753B (en) Treatment of cancer with tor kinase inhibitors
AU2015201138A1 (en) Treatment of cancer with TOR kinase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6